Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Bemarituzumab in solid tumors

Daniel Catenacci • 6 Jul 2020
ESMO WCGIC 2020
Gastroesophageal Cancer Gastrointestinal Cancer General Antibodies Bemarituzumab

Daniel Catenacci, MD, University of Chicago, Chicago, IL, describes a Phase Ib escalation and expansion study of bemarituzumab, an anti-FGFR2 monoclonal antibody, in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Daniel Catenacci

4:10
MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA
Daniel Catenacci • 27 Aug 2021
1:43
Gastroesophageal carcinoma with HER2 gene amplification
Daniel Catenacci • 27 Aug 2021
4:11
Personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Daniel Catenacci • 27 Aug 2021
2:59
Clinical implications of HER2 in GI cancers
Daniel Catenacci • 19 May 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals